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Background: Germ cell tumors (GCT) are the most common solid tumors in adolescent and young adult males
(age 15 and 35 years) and remain one of the most curable of all solid malignancies. However a subset of patients
will have tumors that are refractory to standard chemotherapy agents. The management of this refractory
population remains challenging and approximately 400 patients continue to die every year of this refractory disease
in the United States.
Methods: Given the preclinical evidence implicating vascular endothelial growth factor (VEGF) signaling in the
biology of germ cell tumors, we hypothesized that the vascular endothelial growth factor receptor (VEGFR) inhibitor
sunitinib (Sutent) may possess important clinical activity in the treatment of this refractory disease. We proposed a
Phase II efficacy study of sunitinib in seminomatous and non-seminomatous metastatic GCT’s refractory to first line
chemotherapy treatment (ClinicalTrials.gov Identifier: NCT00912912). Next generation targeted exome sequencing
using HiSeq 2000 (Illumina Inc., San Diego, CA, USA) was performed on the tumor sample of the unusual responder.
Results: Five patients are enrolled into this Phase II study. Among them we report here the clinical course of a
patient (Patient # 5) who had an exceptional response to sunitinib. Next generation sequencing to understand this
patient’s response to sunitinib revealed RET amplification, EGFR and KRAS amplification as relevant aberrations.
Oncoscan MIP array were employed to validate the copy number analysis that confirmed RET gene amplification.
Conclusion: Sunitinib conferred clinical benefit to this heavily pre-treated patient. Next generation sequencing of
this ‘exceptional responder’ identified the first reported case of a RET amplification as a potential basis of sensitivity
to sunitinib (VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor) in a patient with refractory germ cell tumor. Further
characterization of GCT patients using biomarkers for clinical response and patient selection is warranted.
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Germ cell tumors (GCT) are the most common solid tu-
mors in adolescent and young adult males (age 15 and
35 years) and remain one of the most curable of all solid
malignancies [1]. Development of cisplatin-based chemo-
therapy revolutionized the treatment of patients with ad-
vanced GCT; and with better temporal integration of
surgery, dramatic improvements were obtained for patients
presenting with GCT’s. However a subset of patients will
have tumors that are refractory to standard chemotherapy
agents. The management of this refractory population re-
mains challenging and approximately 400 patients con-
tinue to die every year of this refractory disease in the
United States [1-4]. Given the preclinical evidence impli-
cating vascular endothelial growth factor (VEGF) signaling
in the biology of germ cell tumors [5-7], we hypothesized
that the vascular endothelial growth factor receptor
(VEGFR) inhibitor sunitinib (Sutent®) [8] may possess
important clinical activity in the treatment of this re-
fractory disease. We proposed a Phase II efficacy study
of sunitinib in seminomatous and non-seminomatous
metastatic GCT’s refractory to first line chemotherapy
treatment (ClinicalTrials.gov Identifier NCT00912912).
Five patients are enrolled into this a Phase II study.
Among them we report here the clinical course of a pa-
tient (Patient # 5) who had a dramatic response to suni-
tinib. Genome sequencing identified the first reported
case of a RET amplification as a potential basis of sensi-
tivity to sutent in a germ cell tumor.
Patients and methods
Inclusion/Exclusion criteria
This was a phase II study of sunitinib in refractory male
germ cell tumors with the 12 week progression free sur-
vival as the primary endpoint. The major inclusion cri-
teria for the phase II study were progressive metastatic
GCTs of gonadal or extragonadal origin in males after
failure of front-line therapy and at least one salvage regi-
men. In addition the patients must have evaluable or
measurable disease by clinical or radiological studies.
Alternatively, in the absence of radiologically evaluable
or measurable disease, two sequentially rising marker
values each one week apart attributed by treating phys-
ician to germ cell tumor was permitted; either beta HCG
above 50 mIU/ml and/or AFP above 20 ng/ml qualified
as eligible. A major exclusion was prior VEGFR/PDGFR
inhibitor therapy.
Treatment plan
Once registered, treatment was started no later than
7 days. Patients were treated with sunitinib malate 50 mg
orally daily for 4 weeks every 6 weeks. A cycle was defined
as a planned 6-week treatment interval. It was preferred
that patients complete at least 2 cycles of therapy unlessthere is evidence of rapid disease progression. Response
evaluations were performed every 6 weeks according to
RECIST criteria [9,10]. The University of Texas MD
Anderson cancer IRB approved this clinical trial and
all patients were followed according to the protocol. The
trial was an investigator initiated single institutional trial
supported by Pfizer inc. (New York, NY) which provided
Sunitinib (Sutent®) to the patients enrolled on the trial was
closed early due to slow accrual.
Next generation sequencing (T200 platform)
Next generation targeted exomic sequencing was per-
formed for genomic profling.200-500ug of genomic DNA
from each sample was sheared by sonication using the Cov-
aris E220 instrument (Covaris). Library preparation utilized
the KAPA kit following the “with beads” manufacturer
protocol using KAPA HiFi polymerase (6 cycles). The cap-
ture included all exons from 202 cancer-related genes. Bio-
tin labeled DNA probes were designed using Roche
Nimblegen for capturing target regions (over 5,000 exons
in 202 genes) and followed manufacture’s protocol for the
capture process. Probes (50–105 bp long) were tiled at a
minimum coverage of 2× and balanced across the target re-
gions to ensure uniformity. Captured libraries were se-
quenced on a HiSeq 2000 (Illumina Inc., San Diego, CA,
USA) on a version 3 TruSeq paired end flowcell according
to manufacturer’s instructions The resulting BCL files con-
taining the sequence data were converted into “.fastq.gz”
files and individual libraries within the samples were
demultiplexed using CASAVA 1.8.2 with no mismatches.
Deep sequencing data was aligned to to hg19 using
BWA [11]. Duplicate reads were removed via Picard [12].
Single nucleotide variant (SNVs), small indels and and
copy number alterations were called using an in-house
pipeline or a previously published algorithm, respectively
[13]. This supported identifying genome aberrations by
next-generation sequencing (NGS) based assays to identify
genomic alterations in 200 cancer related genes.
Copy number validation
The validation of the copy number alterations, was done
using the OncoScan, a MIParray V3. technology [14].
Results
Five patients are enrolled into this Phase II study; their
clinical characteristics are reported in Table 1. Of the 5
patients evaluable for response, one (20%) was free of
disease progression for more than 12 weeks. We report
the clinical history of the patient that had an unusual
response in detail as below.
Patient clinical history
A 52-year-old Caucasian male had been diagnosed at
age 29 with a right sided testicular GCT. He underwent
Table 1 Characteristics of patients with refractory germ cell tumors enrolled in the sutent phase 2 study and outcomes
at presentation
Pt # Race Age ++ PS Primary
mass






1 AA 17 0 Testis Seminoma;Embryonal,
Choriocarcinoma, Immature
teratoma, Mature teratoma.
R orchiectomy, BEP × 4, RPLND,
TIP, Gem + Etoposide, Avastin +
Gem, Avatin, Taxol, Gem,
18495.6 <1.0 2386
2 Asian 20 0 Mediastinum Yolk sac tumor, Endodermal
Sinus Tumor.
BEP × 3, TIP × 2, Surgery-
multiple, ACE × 2
2087.9 <1.0 419
3 White 36 1 Testis Embryonal Carcinoma (80%)
and yolk sac tumor (20%)
R orchiectomy, BEP × 3, RPLND,
TIP × 4, XRT- T10 -L2 , Cisplatin +
Epirubicin × 4, XRT to R chest
wall, WBRT, Oxaliplatin + Gem, ×
4, Oxaliplatin × 8, Gem × 3,
etoposide × 3
108.9 <1.1 524





BEP × 4, TIP × 1, VIP × 5, HD-SCT
with carboplatin + etoposide,
RPLND,
1.1 227865.8 794
5 White 29 and
52*
1 Testis Embryonal Carcinoma (80%)
and yolk sac tumor (20%)
R orchiectomy, 20 yrs later BEP ×
3, EP × 1, RPLND, TIP × 2, ACE × 1
235.5 19.8 635
Abbreviations: ++Age Age at original diagnosis, PS Performance status, *Age at relapse, AA African American, R Right, BEP Bleiomycin, Etoposide, Cisplatin, RPLND
Retroperitoneal Lymph node dissection, TIP Taxol, Ifosfamide, Cisplatin, VIP VP-16, Ifosfamide, Cisplatin, ACE Actinomycin, Cyclophosphamide, Etoposide.
Gem Gemcitabine.
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The primary tumor was classified as a clinical stage I,
nonseminomatous GCT. AFP level was above 400 prior
to orchiectomy and subsequently normalized appropri-
ately following surgery. He did not receive any adjunctive
chemotherapy. For 15 years, serial CT scans of abdomen
and pelvis along with serum tumor markers found no evi-
dence of tumor recurrence. However, in February 2009, as
a part of work up for abdominal pain, a CT scan of the ab-
domen and pelvis revealed new and multiple enlarged
retroperitoneal lymph nodes (intra-aortocaval and para-
aortic). A subsequent CT of the chest showed bilaterally,
several small, scattered pulmonary nodules; the largest
being a 6 mm × 4 mm, noncalcified nodule in the right,
lower lobe. An MRI of the brain found no evidence of
intracranial metastases. A scrotal ultrasound revealed a
homogenous echo-texture throughout the left testicleFigure 1 CT scans of the Chest in patient # 5 with metastatic platinum
metastatic nodule in the right lung before initiation of sutent B. CT of thewithout evidence of abnormal masses or scars. Serum
alfa-fetoprotein (AFP) and β-hCG levels were elevated at
34.8 ng/ml (normal ranges: 0.0- 5.0) and 22 mIU/ML (0.0-
1.0), respectively.
The patient received standard 3 cycles of bleomycin,
etoposide, and cisplatin(BEP) and 1 cycle of etoposide
and cisplatin (EP). Serum AFP level a month after his
last cycle remained elevated at 56 ng/ml (0.0-5.0). CT scan
of the chest, abdomen and pelvis, post-chemotherapy in
June 2009, continued to show stable small posterior right
lower lobe mass, and a mass in the right retroperitoneum.
Because the patient had persistent back pain that did not
resolve with the resolution of the retroperitoneal adenopa-
thy, an MRI of the spine was performed in July 2009. This
MRI revealed a 2.5 cm enhancing mass in the right retro-
peritoneum at the level of L2. This mass measured 2.7 ×
2.2 cm and comparison to the CT scan done in June 2009refractory gem cell tumor. A: CT of the Chest showing a
Chest showing response of the metastatic nodule in the chest.
Figure 2 Alfa- feto protein (AFP) tumor marker levels: AFP levels and trends before and after Sutent. Arrow points to initiation of Sutent.
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month. The patient was referred to our institution for fur-
ther treatment.
The patient was presented at our multi-disciplinary
tumor board. A decision to proceed to retroperitoneal
lymph node dissection was jointly made. In August
2009 a complete, non-nerve sparing, bilateral retroperi-
toneal lymph node dissection extending from the renal
vessels superiorly to the crossing of the ureters over theFigure 3 Beta-HCG trends before and after sutent. Arrow points to initcommon iliac arteries inferiorly; onto the anterior spin-
ous ligaments posteriorly and laterally to the ureters was
completed without complications. Pathologic review of
the resected tissue demonstrated residual viable malig-
nant GCT within 1 out 9 precaval lymph nodes and 1
out of 8 retrocaval lymph nodes. The histologic classifi-
cation of the GCT was 80% embryonal carcinoma and
20% yolk sac tumor. Following recovery from surgery,
the patient received 2 cycles of adjuvant chemotherapyiation of sutent.









HGNC Alteration Consequence Quality
AKT1 c. G529A p. A117T Likely benign Low
Next generation sequencing of unusual responder patient with testicular
cancer indicated tumor harboring multiple copy number aberrations. Only 5
alterations were found to have reported relevant information in tumors/cells
treated with sunitinib: RET amplification, PTEN loss, EGFR and
KRAS amplification.
HGNC – Hugo genome nomenclature committee, CNV, copy number variation,
SNV- Single nucleotide variants.
NOTE: Genomic alterations detected may or may not have reported altered
protein function.
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This treatment was complicated by acute renal failure and
ifosfamide induced CNS toxicity. Adjuvant chemotherapy
was therefore altered for the third cycle to actinomycin-D,
cyclophosphamide, and etoposide (ACE). A CT abdomen
and pelvis showed no evidence for recurrent disease.
He was followed closely with serial CT scans along with
serum tumor markers. In 2010 a new pulmonary nodule
(Figure 1A) and rising serum tumor markers were de-
tected. He was then enrolled on the clinical study with su-
nitinib for chemotherapy-refractory germ cell tumors in
June 2010. He received sunitinib 50 mg orally for 4 weeks
on and 2 weeks off-cycle. By 09/20010 a decline in serum
tumor markers was observed (Figures 2 and 3; The arrow
points to date of sunitinib initiation). His most significant
response was in serum beta-hCG with a more mild and
fluctuating AFP response. He developed hypothyroidism
while on treatment with sunitinib, a documented side
effect [15] and began levothyroxine therapy with an
appropriate response. He otherwise suffered no other
treatment related G3 or 4 toxicity related to the sunitinib.
Subsequent CT scans show a continued response to the
treatment and has not revealed any new disease sites
(Figure 1B). He continued to be followed up with clinical
and biochemical response with a very good performance
status. Unfortunately, in November 2011, he experienced
progressive weakness of his legs accompanied by saddle
anesthesia, and urinary incontinence. MRI spines showed
progressive disease involving the cauda equina and biopsy
was consistent with metastatic GCT - immunostain re-
sults were positive for cytokeratin, CD30, SALL4, and fo-
cally positive for Oct3/4. He was taken off the study at
that time, 17 months after starting sunitinib. Because of
worsening performance status he elected to receive sup-
portive care and was referred to hospice care.
This patient was enrolled on the unusual responder
program at our institution, a program that applies ap-
propriate next generation sequencing and other genomic
and proteomic technologies to tumor and germline sam-
ples from patients with exceptional responses to chemo-
therapies and targeted regimens in an attempt to identify
potential genetic explanations for the outlier response
[16]. Next generation sequencing of unusual responder
patient with testicular cancer indicated tumor harboring
multiple copy number aberrations. Several genetic alter-
ations were identified in this patient’s tumor. Of these,
some of the variants identified represented potential can-
didates for further exploration to understand this patient’s
response to sunitinib. The only alterations were found to
have reported relevant information in tumors/cells treated
with sunitinib were: RET amplification, PTEN loss, EGFR
and KRAS amplification (Table 2). We carried out an ex-
tensive literature search in National Library of Medicine’s
MEDLINE database on the five alterations and tabulatedthe levels of evidence/significance of genes relevant to su-
nitinib based therapy (Table 3). As the next step, to valid-
ate these genes an oncoscan MIP array were employed to
validate the copy number analysis. The RET amplifica-
tion, EGFR and KRAS amplification were validated by
the second method. The PTEN loss was not validated by
PTEN IHC.
Discussion
We have reported a patient with platinum refractory GCT
who demonstrated clinical and biochemical response to a
targeted therapy with sunitinib in a Phase 2 study. Gen-
ome sequencing uncovered a RET aberration as a plausible
basis for sensitivity of sunitinib. Refractory germ cell tu-
mors that are resistant to cytotoxic chemotherapy are al-
ways challenging and outcomes are poor warranting a
fresh approach. This phase 2 study was designed based on
the rationale that sunitinib was a VEGF inhibitor as there
are several strands of evidence that support consideration
of a role for VEGFR inhibitors in germ cell tumors. The
presence of vascular invasion in Stage I germ cell tumors
was associated with a high risk of relapse after orchiec-
tomy [36]. VEGF expression is strongly correlated with
microvessel density in primary germ cell tumors of the
testis [5,7] and VEGF receptor mRNA is increased in these
tumors [7] suggesting autocrine and/or paracrine signaling
loops driven by VEGF may play an important role in the
angiogenic progression of these tumors. In a study of pa-
tients with seminomatous and non-seminomatous tumors,
VEGF expression was increased compared to normal testis
in both classes of germ cell tumors [5]. Multivariate
analysis in this study indicated microvessel density and
VEGF expression alone were predictive of metastases.
A pre-clinical study showed a significant inhibition in
Table 3 Significance of the alterations relevant to sunitinib
Gene alteration Interpretation
RET_H.AMP RET Amplifications are rare:
• Detected in sporadic anaplastic thyroid cancers and radiation-associated thyroid cancers (Nakashima Hum
Path 2007) maybe as a result of genomic instability [17].
• RET amplifications are rare, mainly RET-PTC1 and RET-PTC3 fustions in thyroid cancer (Marina Melillo J Clin
Invest 2005) [18].
Therapy Significance:
• Lung tumors harboring RET amplification and PTEN deletion were sensitive to sunitinib therapy (Jones
Genome Biol 2010) [19].
• Medullary thyroid cancer patient responds to sunitinib without RET alterations (Bugalho Oncologist 2009) [20].
• Sunitinib inhibits RET/PTC3 fusion phosphorylation causing morphologic reversion of cell transformation
(Kim J Clin Endocrinol Metab 2006) [21].
High level of evidence and
Significance
• Sunitinib selectively inhibits growth of RET/PTC cells (Jeong Cancer Biol Ther 2011) [22].
• Treatment of papillary thyroid cancer patient, but not follicular thyroid carcinoma, with sunitinib resulted in a
dramatic reduction in RET phosphorylation and prolong patient survival (Dawson Anticancer Drugs 2008) [23].
EGFR_H.AMP Therapy Significance:
• Sunitinib treatment of glioblastoma multiforme xenograft tumors harboring EGFR amplification and PTEN
deletion did not impart any in vivo anti-tumor benefit (Joshi PLoS One 2012) [24].
Lowest level of
significance
• Sunitinib had minor anti-proliferative effects (IC50 3 μM) in NSCLC cell lines harbor EGFR T790M and KRAS
mutations, which are resistant to EGFR inhibitors (Pan J Cancer Res Oncol 2011) [25].
KRAS_H.AMP Amplification of proto-oncogenes (wild-type version of oncogene) does not necessarily suggest the ability of
this alteration to transform cell.
• However, studies do show that over expression of WT ras proteins leads to morphological transformation
of cells (Pulciani Mol Cell Biol 1985) [26].
• Focal amplification of KRAS is one of the most common amplification events in lung adenocarcinoma
(Weir Nature 2007; Shiraishi Cancer Res 1989) [27,28].
• Amplification of KRAS is associated with increased protein levels and is quite common in NSCLC (20%;
Wagner AJCP 2009) [29].
Therapy Significance: Mixed data on effecitiveness of Sunitinib in KRAS activated tumors.
• Constitutively active KRAS mutants (G12R) were unresponsive to sunitinib cell growth inhibition in thyroid
carcinoma cell lines (Piscazzi J Clin Endocrinol Metab 2012) [30].
Low level of evidence and
significance
• Sunitinib had minor anti-proliferative effects (IC50 3 μM) in NSCLC cell lines harbor EGFR T790M and KRAS
mutations, which are resistant to EGFR inhibitors (Pan J Cancer Res Oncol 2011) [25].
• Sunitinib reduced tumor size and tumor progression, and prolong median survival in KRAS mutant mouse
NSCLC model (Gandhi Cancer Prev Res 2009) [31].
PTEN_DEL Deletion of PTEN in tumors with oncogene amplifications may be a biomarker for increased tumor sensitivity
(mixed results below, not conclusive).
• Lung tumors harboring RET amplification and PTEN deletion were sensitive to sunitinib therapy (Jones
Genome Biol 2010) [19].
• Sunitinib treatment of glioblastoma multiforme xenograft tumors harboring EGFR amplification and PTEN
deletion did not impart any in vivo anti-tumor benefit (Joshi PLoS One 2012) [24].
Low level of evidence and
significance
• PDGF-driven mouse glioblastoma tumors in PTEN deficient mice had a moderate effect on survival (D’Amico
Neurol Res 2012) [32].
AKT_A117T • Mutation has not been previously reported
• Sunitinib apoptosis mediated through inhibition of AKT signaling in pediatric medulloblastomas (Yang Mol
Cancer Res 2010) [33]. This was likely due to inhibition of upstream RTKs (and no AKT directly).
• Sunitinib decreases phosphorylation of AKT in KIT mutant GIST cell line, as a result of KIT inhibition (Ikezoe
Cancer Sci 2006) [34].
Low level of evidence and
significance
• Reduction of Phospo-AKT in AML cancers harboring FLT3 mutations (Fiedler Blood 2005) [35].
Sunitinib relevant genes for basis of sensitivity, specifically RET amplification, PTEN loss, EGFR and KRAS amplification and a detailed literature search from National
Library of Medicine’s MEDLINE data base.
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of this with cisplatin enhanced these effects [37]. How-
ever, another clinical trial of sunitinib in germ cell
tumors was negative [38] and few case reports have re-
ported responses. In the genomic era patient selection
assumes significance if genomic aberrations in unusual
responders are identified to benefit patient’s with similar
molecular profile.
Sunitinib malate is a potent inhibitor of the tyrosine
kinase activity of the split kinase domain receptor tyro-
sine kinases (RTK’s) VEGFR2 and PDGFR, which are in-
volved in angiogenesis, and the RTKs, KIT, the receptor
for stem cell factor and FLT3, which are involved in
certain solid tumors and hematologic malignancies [8].
NGS sequencing of the unusual responder patient with
testicular cancer indicated tumor harboring a RET amp-
lification. RET is reported to be a therapeutic target of
Sunitinib. Furthermore, one report indicated lung tu-
mors harboring a RET amplification and PTEN deletion
were sensitive to sunitinib therapy [19]. Together these
may explain unusual response of testicular cancer patient
to sunitinib therapy. Pre-clinical studies have shown that
sunitinib inhibits RET/PTC3 fusion phosphorylation caus-
ing morphologic reversion of cell transformation and that
sunitinib inhibits the RET/PTC3 kinase with an IC50 of
224 nm in vitro [21].
Review of literature revealed a report of a phase 2 study
of 10 patients with refractory/metastatic GCT’s using
sunitinib [38]. The investigators of that study reported
that sunitinib caused a transient decrease in serum tumor
markers, but no objective responses were seen in this
small study and concluded that it failed to confer any
benefit [38]. Four of the five initial patients treated on
Feldman et al. trial experienced some tumor marker
decline during the four-week “on” period, followed by
marker rise during the two-week “off” period. In our study
the index patient had a marker drop within the first
4 weeks. There was no considerable time difference in de-
crease of serum tumor markers between the present studyTable 4 Clinical trials and case studies using Sunitinib and Im
Drug Study center/Group Numbe
Sunitinib Canadian Urologic Oncology Group/German 33
Testicular Cancer Study Group cooperative study
Sunitinib Memorial Sloan Kettering Cancer Center 10
Sunitinib Hospital de Dénia, Marina Salud 1
Sunitinib MD Anderson Cancer Center 5
Imatinib Indiana University 6
Imatinib General Hospital Attikon, University of Athens 1
Imatinib Central Hospital of Bolzano, Bolzano, Italy 1
PR- Partial response, PFS – Progression free survival, uPR-unconfirmed partial respoand the referenced study. Sunitinib has been extensively
studied in pre-clinical and clinical models of GCT’s [39].
The pre-clinical studies have been translated only with
modest benefit in clinical studies. These have been tabu-
lated in Table 4.
Identifying the basis of sensitivity can aid in under-
standing the biology of aggressive GCT’s. Moreover, if
validated in other patients with similar biomarker profiles
can prevent the patients without the biomarker from futile
therapy and help patients with biomarker with the appro-
priate molecularly matched therapy. A review published
about targeted therapies on GCT’s catalogued novel ther-
apies in refractory GCT’s and reports that none of the
agents tested including isotretinoin, suramin, arsenic tri-
oxide, thalidomide conferred any benefit in refractory
GCT’s [45,46]. One patient achieved partial response with
a bevacizumab based study with high dose ifosfamide,
cyclophosphamide and etoposide (HD-ICE) and another
patient with c-kit positive seminoma achieved complete
response with imatinib [45]. A different study of 6 patients
with GCT on imatinib reported no benefit from the drug
[45]. Three patients with growing teratoma syndrome in
which the tumor expresses high retinoblastoma protein
(pRB), who were treated with a cyclin-dependent kinase
4/6 (CDK4/6) inhibitor (PD0332991) reported definite
clinical benefit [46,47].
Novel targeted therapies that include small molecule
tyrosine kinase inhibitors and monoclonal antibodies have
changed the landscape in the management for several
solid tumors. We are learning that only a select popula-
tion of patients derives benefit from such agents. The
challenge will be to identify biomarkers of response and/
or resistance and offer a personalized treatment option for
such patients [48].
The case presentation is atypical in that the patient
had a very late relapse 23 years after his original diagno-
sis. This brings up a very important aspect in the follow
up of GCT that they should have annual evaluations for
their whole life even if they reach an asymptomatic stageatinib in relapsed/refractory germ cell tumors
r Efficacy Author Reference
3 PR + 1 uPR RR = 13%
6-mo PFS 11%
K. Oechsle et al. [40]
0 RR, 5 SD Feldman et al. [38]
1 SD, B-HCG drop Gasent Blesa, J. M.et al. [41]
1 /5PR Subbiah et al. Journal of
Hem/Onc
0/6 1 SD 3 mo with >
50% ↓AFP_
Einhorn et al. [42]
1 CR ~32 mo Pectasides, D.et al. [43]
1 CR ~ 24 mo Pedersini R et al. [44]
nse, SD- Stable disease, CR – Complete Response.
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for several reasons. This is one of the first molecularly
targeted therapy agents to induce a durable response in
platinum refractory GCT and the first reported case of a
RET aberration in GCT. One of the major limitations of
the manuscript is lack of functional validations in cell
lines. However, we have validated the exome sequencing
findings using a second method OncoScan, a MIParray
V3. technology which confirmed the RET amplification
in addition to presenting a high level of evidence from a
literature search of the National Library of Medicine’s
MEDLINE data base (Table 3). Further work is needed
to determine the frequency of RET alterations among
patients with relapsed GCT, and to functionally validate
whether RET amplification confers sunitinib sensitivity.
Undoubtedly sunitinib conferred clinical benefit to this
heavily pre-treated patient, and the patient tolerated the
treatment well without any prohibitive toxicity. Moreover,
this novel TKI is oral and conveniently given as a
complete outpatient therapy bestowing a good quality
of life. It would be interesting to study combination of
sunitinib or other novel VEGFR inhibitors with other
agents in poor risk patients with GCT with RET amplifi-
cations. Further characterization of GCT patients using
biomarkers for clinical response and patient selection is
warranted.Competing interests
The authors declare that they have no competing interests.Authors’ contributions
All authors contributed to writing the manuscript. VS, FMB, LCP conceived
the manuscript. LCP is the primary investigator for the clinical trial. VS, FMB,
GBM, KRM, AMB, PR, JFW, and LCP analysed the data. VS, FMB and LCP wrote
the paper. All authors read and approved the final manuscript.Acknowledgements
The Phase 2 clinical trial was supported by Pfizer and Sutent® was provided
by Pfizer.
The next generation sequencing analysis study was supported in part by
Sheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer
Therapy, NCATS grant UL1 TR000371(Center for Clinical and Translational
Sciences), the Bosarge Foundation, and the MD Anderson Cancer Center
Support grant (P30 CA016672).
Author details
1Department of Investigational Cancer Therapeutics, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center, 1515
Holcombe Blvd, Unit 455, Houston, Texas 77030, USA. 2Sheikh Khalifa Bin
Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT), The
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
3Department of Pathology, The University of Texas MD Anderson Cancer
Center, Houston, TX, USA. 4Department of Urology, Division of Surgery, The
University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5Department of Genitourinary Medical Oncology, Division of Cancer
Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX,
USA.
Received: 8 June 2014 Accepted: 7 July 2014
Published: 1 August 2014References
1. Kondagunta GV, Motzer RJ: Chemotherapy for advanced germ cell
tumors. J Clin Oncol 2006, 24(35):5493–5502.
2. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C,
Fossa SD, Skakkebaek NE, de Wit R, Fizazi K, Droz JP, Pizzocaro G, Daugaard G,
de Mulder PH, Horwich A, Oliver T, Huddart R, Rosti G, Paz Ares L, Pont O,
Hartmann JT, Aass N, Algaba F, Bamberg M, Bodrogi I, Bokemeyer C, Classen J,
Clemm S, Culine S, de Wit M, et al: European consensus on diagnosis and
treatment of germ cell cancer: a report of the European Germ Cell Cancer
Consensus Group (EGCCCG). Ann Oncol 2004, 15(9):1377–1399.
3. Sonpavde G, Hutson TE, Roth BJ: Management of recurrent testicular
germ cell tumors. Oncologist 2007, 12(1):51–61.
4. Kollmannsberger C, Nichols C, Bokemeyer C: Recent advances in
management of patients with platinum-refractory testicular germ cell
tumors. Cancer 2006, 106(6):1217–1226.
5. Fukuda S, Shirahama T, Imazono Y, Tsushima T, Ohmori H, Kayajima T, Take S,
Nishiyama K, Yonezawa S, Akiba S, Akiyama S, Ohi Y: Expression of vascular
endothelial growth factor in patients with testicular germ cell tumors as an
indicator of metastatic disease. Cancer 1999, 85(6):1323–1330.
6. Arrieta O, Michel Ortega RM, Angeles-Sanchez J, Villarreal-Garza C,
Aviles-Salas A, Chanona-Vilchis JG, Arechaga-Ocampo E, Luevano-Gonzalez A,
Jimenez MA, Aguilar JL: Serum human chorionic gonadotropin is associated with
angiogenesis in germ cell testicular tumors. J Exp Clin Cancer Res 2009, 28:120.
7. Viglietto G, Romano A, Maglione D, Rambaldi M, Paoletti I, Lago, Califano D,
Monaco C, Mineo A, Santelli G, Manzo G, Botti G, Chiappetta G, Persico MG:
Neovascularization in human germ cell tumors correlates with a marked
increase in the expression of the vascular endothelial growth factor but
not the placenta-derived growth factor. Oncogene 1996, 13(3):577–587.
8. Chow LQ, Eckhardt SG: Sunitinib: from rational design to clinical efficacy.
J Clin Oncol 2007, 25(7):884–896.
9. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L,
Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG:
New guidelines to evaluate the response to treatment in solid tumors.
European Organization for Research and Treatment of Cancer, National
Cancer Institute of the United States, National Cancer Institute of
Canada. J Natl Cancer Inst 2000, 92(3):205–216.
10. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J,
Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R,
Lacombe D, Verweij J: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45(2):228–247.
11. Li H, Durbin R: Fast and accurate short read alignment with
Burrows-Wheeler transform. Bioinformatics 2009, 25(14):1754–1760.
12. DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C,
Philippakis AA, del Angel G, Rivas MA, Hanna M, McKenna A, Fennell TJ,
Kernytsky AM, Sivachenko AY, Cibulskis K, Gabriel SB, Altshuler D, Daly MJ: A
framework for variation discovery and genotyping using next-generation
DNA sequencing data. Nat Genet 2011, 43(5):491–498.
13. Lonigro RJ, Grasso CS, Robinson DR, Jing X, Wu YM, Cao X, Quist MJ,
Tomlins SA, Pienta KJ, Chinnaiyan AM: Detection of somatic copy number
alterations in cancer using targeted exome capture sequencing.
Neoplasia 2011, 13(11):1019–1025.
14. Wang Y, Cottman M, Schiffman JD: Molecular inversion probes: a novel
microarray technology and its application in cancer research.
Cancer Genet 2012, 205(7–8):341–355.
15. Rini BI, Tamaskar I, Shaheen P, Salas R, Garcia J, Wood L, Reddy S, Dreicer R,
Bukowski RM: Hypothyroidism in patients with metastatic renal cell
carcinoma treated with sunitinib. J Natl Cancer Inst 2007, 99(1):81–83.
16. Meric-Bernstam F, Farhangfar C, Mendelsohn J, Mills GB: Building a
personalized medicine infrastructure at a major cancer center. J Clin
Oncol 2013, 31(15):1849–1857.
17. Nakashima M, Takamura N, Namba H, Saenko V, Meirmanov S, Matsumoto N,
Hayashi T, Maeda S, Sekine I: RET oncogene amplification in thyroid cancer:
correlations with radiation-associated and high-grade malignancy.
Hum Pathol 2007, 38(4):621–628.
18. Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G,
Caiazzo F, Basolo F, Giannini R, Kruhoffer M, Orntoft T, Fusco A, Santoro M:
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile
and mitogenic phenotype of thyroid cancer cells. J Clin Investig 2005,
115(4):1068–1081.
19. Jones SJ, Laskin J, Li YY, Griffith OL, An J, Bilenky M, Butterfield YS, Cezard T,
Chuah E, Corbett R, Fejes AP, Griffith M, Yee J, Martin M, Mayo M, Melnyk N,
Subbiah et al. Journal of Hematology & Oncology 2014, 7:52 Page 9 of 9
http://www.jhoonline.org/content/7/1/52Morin RD, Pugh TJ, Severson T, Shah SP, Sutcliffe M, Tam A, Terry J,
Thiessen N, Thomson T, Varhol R, Zeng T, Zhao Y, Moore RA, Huntsman DG,
et al: Evolution of an adenocarcinoma in response to selection by
targeted kinase inhibitors. Genome Biol 2010, 11(8):R82.
20. Bugalho MJ, Domingues R, Borges A: A case of advanced medullary
thyroid carcinoma successfully treated with sunitinib. Oncologist 2009,
14(11):1083–1087.
21. Kim DW, Jo YS, Jung HS, Chung HK, Song JH, Park KC, Park SH, Hwang JH,
Rha SY, Kweon GR, Lee SJ, Jo KW, Shong M: An orally administered
multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor
of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin
Endocrinol Metab 2006, 91(10):4070–4076.
22. Jeong WJ, Mo JH, Park MW, Choi IJ, An SY, Jeon EH, Ahn SH: Sunitinib
inhibits papillary thyroid carcinoma with RET/PTC rearrangement but not
BRAF mutation. Cancer Biol Ther 2011, 12(5):458–465.
23. Dawson SJ, Conus NM, Toner GC, Raleigh JM, Hicks RJ, McArthur G,
Rischin D: Sustained clinical responses to tyrosine kinase inhibitor
sunitinib in thyroid carcinoma. Anti-Cancer Drugs 2008, 19(5):547–552.
24. Joshi AD, Loilome W, Siu IM, Tyler B, Gallia GL, Riggins GJ: Evaluation of
tyrosine kinase inhibitor combinations for glioblastoma therapy.
PLoS ONE 2012, 7(10):e44372.
25. Pan F, Tian J, Zhang X, Zhang Y, Pan Y: Synergistic interaction between
sunitinib and docetaxel is sequence dependent in human non-small
lung cancer with EGFR TKIs-resistant mutation. J Cancer Res Clin Oncol
2011, 137(9):1397–1408.
26. Pulciani S, Santos E, Long LK, Sorrentino V, Barbacid M: Ras gene
amplification and malignant transformation. Mol Cell Biol 1985,
5(10):2836–2841.
27. Weir BA, Woo MS, Getz G, Perner S, Ding L, Beroukhim R, Lin WM,
Province MA, Kraja A, Johnson LA, Shah K, Sato M, Thomas RK, Barletta JA,
Borecki IB, Broderick S, Chang AC, Chiang DY, Chirieac LR, Cho J, Fujii Y,
Gazdar AF, Giordano T, Greulich H, Hanna M, Johnson BE, Kris MG, Lash A,
Lin L, Lindeman N, et al: Characterizing the cancer genome in lung
adenocarcinoma. Nature 2007, 450(7171):893–898.
28. Shiraishi M, Noguchi M, Shimosato Y, Sekiya T: Amplification of
protooncogenes in surgical specimens of human lung carcinomas.
Cancer Res 1989, 49(23):6474–6479.
29. Wagner PL, Perner S, Rickman DS, LaFargue CJ, Kitabayashi N, Johnstone SF,
Weir BA, Meyerson M, Altorki NK, Rubin MA: In situ evidence of KRAS
amplification and association with increased p21 levels in non-small cell
lung carcinoma. Am J Clin Pathol 2009, 132(4):500–505.
30. Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AM, Antonetti R,
Cignarelli M, Landriscina M: Activation of the RAS/RAF/ERK signaling
pathway contributes to resistance to sunitinib in thyroid carcinoma cell
lines. J Clin Endocrinol Metab 2012, 97(6):E898–E906.
31. Gandhi L, McNamara KL, Li D, Borgman CL, McDermott U, Brandstetter KA,
Padera RF, Chirieac LR, Settleman JE, Wong KK: Sunitinib prolongs survival
in genetically engineered mouse models of multistep lung
carcinogenesis. Cancer Prev Res (Phila) 2009, 2(4):330–337.
32. D'Amico R, Lei L, Kennedy BC, Sisti J, Ebiana V, Crisman C, Christensen JG,
Gil O, Rosenfeld SS, Canoll P, Bruce JN: The addition of Sunitinib to
radiation delays tumor growth in a murine model of glioblastoma.
Neurol Res 2012, 34(3):252–261.
33. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H: Sunitinib induces
apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting
STAT3 and AKT signaling pathways. Mol Cancer Res 2010, 8(1):35–45.
34. Ikezoe T, Yang Y, Nishioka C, Bandobashi K, Nakatani H, Taguchi T, Koeffler HP,
Taguchi H: Effect of SU11248 on gastrointestinal stromal tumor-T1 cells:
enhancement of growth inhibition via inhibition of 3-kinase/Akt/
mammalian target of rapamycin signaling. Cancer Sci 2006, 97(9):945–951.
35. Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann OG, O'Farrell AM,
Bello CL, Allred R, Manning WC, Cherrington JM, Louie SG, Hong W,
Brega NM, Massimini G, Scigalla P, Berdel WE, Hossfeld DK: A phase 1 study
of SU11248 in the treatment of patients with refractory or resistant
acute myeloid leukemia (AML) or not amenable to conventional therapy
for the disease. Blood 2005, 105(3):986–993.
36. Albers P, Siener R, Kliesch S, Weissbach L, Krege S, Sparwasser C, Schulze H,
Heidenreich A, de Riese W, Loy V, Bierhoff E, Wittekind C, Fimmers R,
Hartmann M: Risk factors for relapse in clinical stage I nonseminomatous
testicular germ cell tumors: results of the German Testicular Cancer
Study Group Trial. J Clin Oncol 2003, 21(8):1505–1512.37. Castillo-Avila W, Piulats JM, Garcia Del Muro X, Vidal A, Condom E,
Casanovas O, Mora J, Germa JR, Capella G, Villanueva A, Vinals F: Sunitinib
inhibits tumor growth and synergizes with cisplatin in orthotopic
models of cisplatin-sensitive and cisplatin-resistant human testicular
germ cell tumors. Clin Cancer Res 2009, 15(10):3384–3395.
38. Feldman DR, Turkula S, Ginsberg MS, Ishill N, Patil S, Carousso M, Bosl GJ,
Motzer RJ: Phase II trial of sunitinib in patients with relapsed or
refractory germ cell tumors. Invest New Drugs 2010, 28(4):523–528.
39. Juliachs M, Munoz C, Moutinho CA, Vidal A, Condom E, Esteller M, Graupera M,
Casanovas O, Germa JR, Villanueva A, Vinals F: The PDGFRbeta-AKT pathway
contributes to CDDP-acquired resistance in testicular germ cell tumors.
Clin Cancer Res 2014, 20(3):658–667.
40. Oechsle K, Honecker F, Cheng T, Mayer F, Czaykowski P, Winquist E,
Wood L, Fenner M, Glaesener S, Hartmann JT, Chi K, Bokemeyer C,
Kollmannsberger C: Preclinical and clinical activity of sunitinib in patients
with cisplatin-refractory or multiply relapsed germ cell tumors: a
Canadian Urologic Oncology Group/German Testicular Cancer Study
Group cooperative study. Ann Oncol 2011, 22(12):2654–2660.
41. Gasent Blesa JM, Grande Pulido E, Laforga Canales J, Alberola Candel V:
Final report of the first refractory germ cell tumor treated with Sunitinib
Malate. Case Rep Oncol 2009, 2(3):234–241.
42. Einhorn LH, Brames MJ, Heinrich MC, Corless CL, Madani A: Phase II study
of imatinib mesylate in chemotherapy refractory germ cell tumors
expressing KIT. Am J Clin Oncol 2006, 29(1):12–13.
43. Pectasides D, Nikolaou M, Pectasides E, Koumarianou A, Valavanis C,
Economopoulos T: Complete response after imatinib mesylate
administration in a patient with chemoresistant stage IV seminoma.
Anticancer Res 2008, 28(4C):2317–2320.
44. Pedersini R, Vattemi E, Mazzoleni G, Graiff C: Complete response after
treatment with imatinib in pretreated disseminated testicular seminoma
with overexpression of c-KIT. Lancet Oncol 2007, 8(11):1039–1040.
45. Fenner MH, Beutel G, Grunwald V: Targeted therapies for patients with
germ cell tumors. Expert Opin Investig Drugs 2008, 17(4):511–522.
46. Veenstra CM, Vaughn DJ: Third-line chemotherapy and novel agents
for metastatic germ cell tumors. Hematol Oncol Clin North Am 2011,
25(3):577–591. ix.
47. Vaughn DJ, Flaherty K, Lal P, Gallagher M, O’Dwyer P, Wilner K, Chen I,
Schwartz G: Treatment of growing teratoma syndrome. N Engl J Med
2009, 360(4):423–424.
48. Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J,
Zweibel J, Collins J, Doroshow JH: Utilizing targeted cancer therapeutic
agents in combination: novel approaches and urgent requirements.
Nat Rev Drug Discov 2011, 9(11):843–856.
49. Gerl A, Clemm C, Schmeller N, Hentrich M, Lamerz R, Wilmanns W: Late
relapse of germ cell tumors after cisplatin-based chemotherapy.
Ann Oncol 1997, 8(1):41–47.
50. Baniel J, Foster RS, Gonin R, Messemer JE, Donohue JP, Einhorn LH: Late
relapse of testicular cancer. J Clin Oncol 1995, 13(5):1170–1176.
doi:10.1186/s13045-014-0052-x
Cite this article as: Subbiah et al.: Next generation sequencing analysis
of platinum refractory advanced germ cell tumor sensitive to Sunitinib
(Sutent ®) a VEGFR2/PDGFRβ/c-kit/ FLT3/RET/CSF1R inhibitor in a phase
II trial. Journal of Hematology & Oncology 2014 7:52.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
